Open Philanthropy recommended a grant of $630,123 over three years to the University Of Science Technical And Technologies De Bamako to participate in a phase III clinical trial of a malaria vaccine developed by the Jenner Institute at the University of Oxford. Dr. Alassane Dicko will serve as the University’s principal investigator. The trial, funded by the Serum Institute of India, will be conducted in collaboration with the Institut des Sciences et Techniques, Bobo-Dioulasso; the Institut de Recherche en Sciences de la Santé; the KEMRI Wellcome Trust Research Programme; and the Ifakara Health Institute.
Open Philanthropy recommended a grant of $631,162 over three years to the Institut des Sciences et Techniques, Bobo-Dioulasso to participate in a phase III clinical trial of a malaria vaccine developed by the Jenner Institute at the University of Oxford. Dr. Jean Bosco Ouedraogo will serve as the Institut’s principal investigator. The trial, funded by the Serum Institute of India, will be conducted in collaboration with the University Of Science Technical And Technologies De Bamako, the Institut de Recherche en Sciences de la Santé, the KEMRI Wellcome Trust Research Programme, and the Ifakara Health Institute.
Open Philanthropy recommended a grant of $630,123 over three years to the Institut de Recherche en Sciences de la Santé to participate in a phase III clinical trial of a malaria vaccine developed by the Jenner Institute at the University of Oxford. Dr. Halidou Tinto will serve as the Institut’s principal investigator. The trial, funded by the Serum Institute of India, will be conducted in collaboration with the University Of Science Technical And Technologies De Bamako; the Institut des Sciences et Techniques, Bobo-Dioulasso; the KEMRI Wellcome Trust Research Programme; and the Ifakara Health Institute.
Open Philanthropy recommended a grant of $472,016 over three years to The KEMRI-Wellcome Trust Research Programme to participate in a phase III clinical trial of a malaria vaccine developed by the Jenner Institute at the University of Oxford. Dr. Philip Bejon will serve as the Programme’s principal investigator. The trial, funded by the Serum Institute of India, will be conducted in collaboration with the University Of Science Technical And Technologies De Bamako; the Institut des Sciences et Techniques, Bobo-Dioulasso; the Institut de Recherche en Sciences de la Santé; and the Ifakara Health Institute.
Image courtesy of the University of California, San Diego.
Open Philanthropy recommended a grant of $190,000 to the University of California, San Diego to support Professor Omar Akbari and two collaborators at UC Berkeley and the London School of Hygiene & Tropical Medicine. They will model the costs and benefits of implementing Professor Akbari’s pgSIT method to suppress transmission of malaria in peri-urban areas of Africa.
Open Philanthropy recommended a grant of $2,500,000 over three years to the International Vaccine Institute (IVI) to support a phase I clinical trial of a conjugate vaccine for cholera. IVI will run the clinical trial in partnership with EuBiologics. The trial will be conducted in South Korea with a focus on safety and tolerability in humans, and will test different doses and formulations for the vaccine.
This falls within our focus area of scientific research, and specifically within our interest in advancing human health and wellbeing.
Open Philanthropy recommended two grants totaling $8,500 to the International Genetically Engineered Machine (iGEM) Foundation to cover the registration fees for Africa Biosynthetic Solutions and Innovations, Kenya (Team ABSI_Kenya), to participate in the iGEM Synthetic Biology competition, which we have previously funded. Team ABSI_Kenya is a team of young Kenyan scientists from various disciplines who are working to develop a biosensor and filter to detect and remove microbial and chemical contaminants in drinking water in low-resource settings.
This page was reviewed but not written by the grant investigators. Yale University staff also reviewed this page prior to publication.
Open Philanthropy recommended a grant of $360,000 to Yale University to support research led by Dr. Richard Bucala on the effectiveness of a vaccine against malaria infections. The vaccine targets the immune-suppressive macrophage migration inhibitory factor protein produced by plasmodium falciparum, the parasite that causes malaria in humans. If effective, the vaccine may also protect against hookworm and other parasitic infections involving the same protein. Dr. Bucala’s work will be done in collaboration with Dr. Adrian Hill of the University of Oxford.
Open Philanthropy recommended a grant of $50,000 to Kansas State University to support the Fungal Genetics Stock Center. This funding is intended to support research on the biological mechanisms of filamentous fungi in order to better understand how to prevent fungal infections, which cause approximately 1.6 million deaths each year.
